ArticleThe pharmacogenomics journal2012
Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
Article in The pharmacogenomics journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- An Enhanced Multiple Sclerosis Disease Diagnosis via an Ensemble Approach.Diagnostics (Basel, Switzerland) · 2022Article
- Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE.Journal of autoimmunity · 2020Article
- Article
- Elastic net-based prediction of IFN-β treatment response of patients with multiple sclerosis using time series microarray gene expression profiles.Scientific reports · 2019Article
- Neglected Functions of TFCP2/TFCP2L1/UBP1 Transcription Factors May Offer Valuable Insights into Their Mechanisms of Action.International journal of molecular sciences · 2018Review
- Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.CNS neuroscience & therapeutics · 2018Article
- Blood Transcriptome Profiling in Myasthenia Gravis Patients to Assess Disease Activity: A Pilot RNA-seq Study.Experimental neurobiology · 2016Article
- Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.Expert review of clinical immunology · 2015Review
- Review
- A bayesian framework that integrates heterogeneous data for inferring gene regulatory networks.Frontiers in bioengineering and biotechnology · 2014Review
- Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.Molecular neurobiology · 2013Article
- MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.International journal of molecular sciences · 2013Article
- Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells.PloS one · 2013Article
- Integrating external biological knowledge in the construction of regulatory networks from time-series expression data.BMC systems biology · 2012Article
- Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.Journal of neuroinflammation · 2012Article
- Gene expression profiling in multiple sclerosis brain.Neurobiology of disease · 2012Review
- Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis.PloS one · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon-β (IFN-β) is one of the major drugs for multiple sclerosis (MS) treatment. The purpose of this study was to characterize the transcriptional effects induced by intramuscular IFN-β-1a therapy in patients with relapsing-remitting form of MS. By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells of 24 MS patients within the first 4 weeks of IFN-β administration. We identified 121 genes that were significantly up- or downregulated compared with baseline, with stronger changed expression at 1 week after start of therapy. Eleven transcription factor-binding sites (TFBS) are overrepresented in the regulatory regions of these genes, including those of IFN regulatory factors and NF-κB. We then applied TFBS-integrating least angle regression, a novel integrative algorithm for deriving gene regulatory networks from gene expression data and TFBS information, to reconstruct the underlying network of molecular interactions. An NF-κB-centered sub-network of genes was highly expressed in patients with IFN-β-related side effects. Expression alterations were confirmed by real-time PCR and literature mining was applied to evaluate network inference accuracy.
Indexed as
Identifiers
20956993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.